Fiera Capital (Canada)
CRNX

Fiera Capital (Canada)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Fiera Capital (Canada)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Sell
338,841
-250,813
-43% -$9.32M 0.05% 197
2026
Q1 		$21.4M Buy
589,654
+11,199
+2% +$500K 0.07% 185
2025
Q4 		$26.9M Buy
578,455
+143,030
+33% +$6.37M 0.09% 164
2025
Q3 		$18.1M Sell
435,425
-8,905
-2% -$285K 0.06% 168
2025
Q2 		$12.8M Buy
444,330
+5,993
+1% +$185K 0.04% 174
2025
Q1 		$14.7M Sell
438,337
-16,645
-4% -$622K 0.05% 172
2024
Q4 		$23.3M Sell
454,982
-11,093
-2% -$621K 0.07% 142
2024
Q3 		$23.8M Sell
466,075
-14,334
-3% -$739K 0.07% 145
2024
Q2 		$21.5M Buy
480,409
+4,899
+1% +$226K 0.07% 142
2024
Q1 		$22.3M Buy
+475,510
New +$18.6M 0.06% 144

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiera Capital (Canada)'s CRNX Position: Q2 2026 in Review

Fiera Capital (Canada) reduced its Crinetics Pharmaceuticals (CRNX) stake by 43% in Q2 2026, selling an estimated $9.32M and leaving 338,841 shares worth $12.7M. The position accounts for 0.05% of the portfolio, ranked #197.

Fiera Capital (Canada) first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $26.9M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Fiera Capital (Canada) held 338,841 shares of Crinetics Pharmaceuticals worth $12.7M as of Q2 2026.
  • Fiera Capital (Canada) sold 250,813 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $9.32M.
  • Crinetics Pharmaceuticals made up 0.05% of Fiera Capital (Canada)'s portfolio in Q2 2026, its #197 holding.
  • Fiera Capital (Canada) first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Fiera Capital (Canada)'s Crinetics Pharmaceuticals position peaked at $26.9M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Fiera Capital (Canada)'s 13F filing for Q2 2026, filed 7 Aug 2026.